Comparative Effectiveness of Rehabilitation Programs for Adults with Post-Tuberculosis Lung Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
In brief
One tuberculosis rehabilitation trial improved walking distance by 87 meters
In a 120-person randomized trial, rehabilitation improved six-minute walking distance by 87 meters compared with the control group. Across seven trial reports, however, evidence for exercise capacity and other outcomes was rated very uncertain, and only two comparable trials informed the main pooled exercise estimate, which was extremely imprecise. The size and generalizability of any benefit remain unclear.
- Journal
- Journal of clinical medicine (Q1)
- Published
- 28 October 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Marin Vlăduț Piciorea, Gabriela-Marina Andrei, Mihai Olteanu, Daniela Matei, Mihaela Ionescu, Magdalena Rodica Trăistaru
- PMID
- 43030541
- DOI
- 10.3390/jcm15218397
Why clinicians should know about it
- Picked for Pulmonary and Respiratory Medicine (top studies of the week, 15 November 2026): Systematic review of rehabilitation for post-tuberculosis lung disease
Abstract
Background: Persistent respiratory and functional impairments after pulmonary tuberculosis can reduce exercise capacity and health-related quality of life. This systematic review and meta-analysis evaluated structured rehabilitation in adults with post-tuberculosis lung disease (PTLD). Methods: The review followed PRISMA 2020 and was prospectively registered in PROSPERO (CRD420261338253). PubMed/MEDLINE, Scopus, Web of Science Core Collection, CENTRAL, and PEDro were searched from inception, with final bibliographic updating through 5 September 2026 and trial registry cross-linking through 28 August 2026. Results: Seven randomized trial reports were included. Two directly comparable adjusted ISWT trials are presented as the main exercise capacity findings: a study published in 2026 reported +54.36 m (95% CI 17.22 to 91.51) and a research conducted in 2026 reported +123.0 m (95% CI 81.1 to 164.8). The pooled random-effects estimate was +87.98 m (95% Hartung-Knapp CI -348.01 to 523.96), but this estimate is presented secondarily because the interval was extremely wide with only two contributing trials. A 120-participant RCT reported an adjusted 6MWD benefit of +87.4 m (95% CI 74.2 to 100.6). A newly identified three-arm RCT (n = 180) reported statistically significant omnibus between-group differences, but substantial baseline imbalance and unusual control group reporting patterns limit device-versus-control interpretation. Certainty was very low for exercise capacity, dyspnea, health-related quality of life, pulmonary function, inspiratory muscle strength, and adverse events. Conclusions: Accordingly, the evidence is very uncertain regarding the effects of structured rehabilitation on these outcomes and regarding the magnitude and generalizability of any benefit in PTLD.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.